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302Objective: Adult postcardiotomy cardiogenic shock potentially requiring mechanical circulatory support occurs
in 0.5% to 1.5% of cases. Risk factors influencing early or long-term outcome after extracorporeal membrane
oxygenation implantation are not well described.
Methods: Between May 1996 and May 2008, 517 adult patients received extracorporeal membrane oxygenation
support for postcardiotomy cardiogenic shock. Procedures were isolated coronary artery bypass grafting (37.4%),
isolated valve surgery (14.3%), coronary artery bypass grafting plus valve surgery (16.8%), thoracic organ trans-
plantion (6.5%), and other combinations (25.0%). Fifty-four preoperative and 42 procedural risk factors concern-
ing in-hospital mortality were evaluated by logistic regression analyses.
Results: Mean age was 63.5 years, 71.5% were male, ejection fraction was 45.9%  17.6%, logistic Euro-
SCORE was 21.6%  20.7%. Extracorporeal membrane oxygenation was established through thoracic
(60.8%) or extrathoracic (39.2%) cannulation. Extracorporeal membrane oxygenation support was 3.28 
2.85 days. Intra-aortic balloon pumps were implanted in 74.1%. Weaning from extracorporeal membrane oxy-
genation was successful for 63.3%, and 24.8%were discharged. Cerebrovascular events occurred in 17.4%, gas-
trointestinal complications in 18.8%, and renal replacement therapy in 65.0%. Risk factors for hospital mortality
were age older than 70 years (odds ratio, 1.6), diabetes (odds ratio, 2.5), preoperative renal insufficiency (odds
ratio, 2.1), obesity (odds ratio, 1.8), logistic EuroSCORE greater than 20% (odds ratio, 1.8), operative lactate
greater than 4 mmol/L (odds ratio, 2.2). Isolated coronary artery bypass grafting (odds ratio, 0.44) was protective.
Cumulative survivals were 17.6% after 6 months, 16.5% after 1 year, and 13.7% after 5 years.
Conclusions: Extracorporeal membrane oxygenation support is an acceptable option for patients with postcar-
diotomy cardiogenic shock who otherwise would die and is justified by good long-term outcome of hospital sur-
vivors. Because of high morbidity and mortality, extracorporeal membrane oxygenation must be decided by
individual risk profile. (J Thorac Cardiovasc Surg 2010;139:302-311)Supplemental material is available online.
The incidence of refractory postcardiotomy cardiogenic
shock (PCS) in adult cardiac surgical patients ranges from
0.5% to 1.5% but depends highly on the surgical case
mix.1,2 For these patients, the implantation of an extracorpo-
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The Journal of Thoracic and Cardiovascular Surgapplicable and widely accepted option for temporary me-
chanical circulatory support allowing cardiac and pulmo-
nary recovery or bridging until further therapeutic
alternatives can be carefully considered.3-5 During the last
20 years however, ECMO results in these patients have
not been satisfactory. Successful ECMO weaning rate
ranges from 31% to 60% and corresponds with an in-hospi-
tal mortality of 59% to 84%.2-11 By indication, acute myo-
cardial failure is the major cause of mortality, although
a significant number of other primary causes of death have
also been reported.12
The perioperative decision for ECMO support in PCS
remains difficult and is based on scientific data but also on
individual considerations, because ECMO support is associ-
ated with a high morbidity that includes bleeding, ischemic
or thromboembolic events, and end-organ failures. Surgeons
have to carefully balance the high perioperative morbidity,
staffing needs, and resource use in ECMO treatment against
the probability of survival. Although an unexpected PCS
event in a low-risk patient is usually an indicator forery c February 2010
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
IABP ¼ intra-aortic balloon pump
OR ¼ odds ratio
PCS ¼ postcardiotomy cardiogenic shock
L-VAD ¼ left ventricular assist device
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Da more liberal ECMO indication, indications might be more
restrictive in high-risk patients and preoperatively foresee-
able PCS. The prognostic effects of varying risk factors, in-
cluding patient characteristics, surgical procedures, and
technical ECMO implantation details have not been well
considered. The aim of this study was therefore to use uni-
variate and multivariate logistic regression models to iden-
tify risk factors that potentially affect hospital and long-
term outcomes.MATERIALS AND METHODS
Patients and Procedures
Between May 1996 and May 2008, a total of 517 of 40,538 patients
(1.28%) received venoarterial ECMO implantation to treat refractory
PCS. ECMOwas instituted intraoperatively during the primary cardiac pro-
cedure or secondarily within 30 minutes of deciding to support a patient
with delayed PCS. Secondary indications included progressive univentric-
ular or biventricular forward or backward pump failure, intractable ventric-
ular arrhythmia or fibrillation, or sudden cardiac death of primary unknown
reasons.
For all patientswithECMO,multiple preoperative, perioperative, andpost-
operative clinical variables were prospectively recorded in the hospital data-
base. Fifty-four preoperative and 42 procedural variables were evaluated by
univariate und multivariate logistic regression analysis with respect to in-hos-
pital mortality. Follow-upwas complete at a mean of 3.2 years for the hospital
survivors.
ECMO Device and Management
Arterial cannulation site was central in 60.8% and peripheral in 39.2%
(30.3% axillary artery access and 69.7% femoral artery access). The fem-
oral artery was directly cannulated by Seldinger technique, and the axillary
artery was approached through a 6- or 8-mm Dacron polyester fabric pros-
thesis. In 23.4% of femoral artery approaches, a distal leg perfusion cannula
(8F or 10F) was introduced. Venous line was inserted by right atrial cannu-
lation in 61.8% and by femoral venous cannulation in 48.2% (42.1% per-
cutaneously, 57.9% by surgical cutdown). In 10% of cases, combined right
atrial and femoral venous drainage was established.
Themost common indication for ECMOduring heart surgery was for pa-
tients who could not be weaned from cardiopulmonary bypass. For these pa-
tients, the existing right atrial and aortic cannulas were mostly used. In a few
cases, central cannulation was converted to peripheral cannulation to allow
primary chest closure. In patients receiving ECMO secondary to heart sur-
gery, ECMO was implanted through peripheral cannulation, or, when addi-
tional cardiac surgery or cardiac reexploration was indicated, by central
insertion. Overall in 50.8% of all cases the chest remained open after
ECMO implantation (Table E1).
The institutional ECMO cannulation techniques and management strat-
egies have been previously described.2,12 In brief, the ECMO circuit con-
sisted of a centrifugal pump console (in most cases, Biopump PB-80;
Medtronic Bio-Medicus, Minneapolis, Minn) in conjunction with an in-The Journal of Thoracic and Caline plasma-tight hollow-fiber microporous membrane oxygenator (Affinity
NTTM;Medtronic, Anaheim, Calif; or Hilite 7000 LTTM;MedosMedizin-
technik AG, Stolberg, Germany) with integrated heat exchanger. All com-
ponents were heparin bonded and connected by the shortest possible tubing
system. Routinely, no additional left-sided venting or atrial septostomy was
performed. The ECMO systemwas implanted under full heparinization, and
activated clotting time was kept longer than 300 seconds. Usually half of the
heparin was antagonized with protamine once full ECMO flow was estab-
lished, aiming for an activated clotting time of 160 seconds. Until the
year 2006, aprotinin was routinely administered with a modified Hammer-
smith protocol. More recently, aprotinin was replaced by tranexamic acid.
Additional coagulation factors, platelets, or coagulant agents were specifi-
cally substituted according to the results of laboratory coagulation analysis
or thromboelastography. If bleeding was acceptable, the patients were given
continuous heparinization as early as possible to maintain an activated clot-
ting time of 160 seconds. If it had not already been done, all patients with
coronary artery disease and almost all other patients received intra-aortic
balloon pump (IABP) insertion to compensate systemic afterload increase
induced by ECMO and to generate pulsatility. With full ECMO support,
the goal was to reduce intravenous inotropes and to decrease ventilation
to lower positive end-expiratory pressures (5 cm H2O) and physiologic
respiratory minute volumes to allow optimal myocardial and pulmonary
recoveries. Fractional inspired oxygen was adjusted to maintain PO2
between 85 and 100 mm Hg. The oxygenator was examined twice a day
for early detection of thrombus formations. It was exchanged in the event
of thrombus detection or if the perfusion pressure started to increase. Plate-
lets were substituted to achieve a platelet account of 50,000 to 100,000 cells/
mL. Blood clotting factors were analyzed daily and substituted when cross-
ing lower limits. Cardiopulmonary recovery was daily assessed by hemody-
namic, clinical, and echocardiographic measurements to define the optimal
time of weaning.
Routinely, full ECMO flow was instituted for 48 to 72 hours before the
weaning process was started.Weaningwas cautiously begun only under sta-
ble hemodynamic and metabolic conditions, starting from full flow to ap-
proximately 1 L/min during a 36- to 48-hour process of observing
intrinsic cardiac output, metabolic status, venous saturation, and end-organ
perfusion, allowing medical adjustment when necessary. When signs of
malperfusion occurred during ECMO weaning, the flow was increased
again to full, allowing prolonged ECMO support and exclusion of cardiac
tamponade. During the weaning, all patients underwent at least 1 daily con-
trol transesophageal echocardiogram. Before ECMO weaning, bronchos-
copy was performed on a routine basis. Even if bridging for recovery was
the initial goal, in all cases treatment options including bridging to ventric-
ular assist device implantation and transplantion were considered individu-
ally, and preparations were made in case weaning was unsuccessful. When
cardiac transplantion was contraindicated in a patient with irreversible ven-
tricular failure, ECMO support was withdrawn with the awareness that sur-
vival was unlikely.
Patients with ECMO were managed by the on-shift intensivists and the
on-shift cardiac surgeons on a 24-hour basis. Routinely, the patient-to-nurse
ratio was reduced from 2:1 to 1:1 during the first 24 hours of the ECMO run.
Further personal management depended on the efforts that had to be made
for the individual patient with ECMO. Routinely a perfusionist checked the
ECMO circuit at least twice a day.Definitions
Indication for ECMO support included clinical criteria of PCS such as
systolic arterial hypotension (<80 mm Hg) and signs of end-organ failure,
anaerobic metabolism, and metabolic acidosis (pH<7.3, lactate level>3.0
mmol/L, urinary rate<0.5 mL/kg) despite optimized supportive measures
such as IABP, inotropes, nitric oxide, and phosphodiesterase inhibitors. He-
modynamic criteria were cardiac index less than 1.8 L/m2 body surface area
and pulmonary capillarywedge pressure of at least 20mmHg. Cardiac func-
tion was reassessed by transesophageal echocardiography in all cases.rdiovascular Surgery c Volume 139, Number 2 303
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DPerioperative acute myocardial infarction (AMI) was assumed in cases
of creatinine kinase MB fraction release more than 5-fold the upper limit of
normal during the perioperative period. According to this definition, an
AMI was assumed when creatine kinase MBwas higher than 120 units/L. Di-
abetes was defined as hyperglycemia requiring either insulin or noninsulin
treatment, and chronic renal insufficiency was noted for patients with creati-
nine plasma levels greater than 1.8 mg/dL. Weaning was considered as suc-
cessful when a patient survived ECMO explantation for longer than 6 hours.
Statistics
Data were 100% complete. Continuous variables are expressed as mean
 SD for Gaussian distributions and as mean values only otherwise. Cate-
goric data are given as proportions. Categoric variables were compared
with the Pearson c2 test, and independent continuous variables were com-
pared with 2-tailed Student t test or Mann–Whitney U test as appropriate.
Univariate and stepwise multivariate logistic regression analyses of 54 di-
chotomous preoperative and 42 perioperative risk factors for in-hospital
mortality were performed by calculating the odds ratio (OR) with 95% con-
fidence interval. Risk factors analyzed are listed in Tables 1 through 3 andE1
Cumulative survivals were calculated by Kaplan–Meier methods with
95% confidence limits. The statistical calculations were performed with
the 17.0 SPSS (SPSS, Inc, Chicago, Ill) and Microsoft Excel 2003 (Micro-
scoft Corp, Redmond, Wash) software packages. The study protocol and
anonymous data publication were approved by the local ethics committee.
There are no disclosures or funding to declare.RESULTS
For baseline extracardiac and cardiac characteristics of the
patients undergoing ECMO and their effects on hospital sur-
vival, see Table 1 and Figure E1. The underlying cardiac dis-
eases and corresponding cardiac procedures are presented in
Tables 2 and 3. Age ranged from 18 to 84 years.
ECMO was established during the initial cardiac surgery
in 41.9% of cases because of circulatory instability during or
immediately after weaning from cardiopulmonary bypass.
Most of the patients (58.1%) received ECMO secondary to
primary cardiac surgery as a consequence of delayed PCS or
resuscitation in the postoperative course. Mean interval to pri-
mary cardiac procedure in these patients was 62.6 hours, and
there was greater postponement among nonsurvivors (71.7
hours) than among hospital survivors (33.3 hours, P ¼
.031). Overall delayedECMO implantation was not associated
with a significantly increased in-hospital mortality relative to
simultaneous ECMO implantation (OR, 1.20; P ¼ .404). In
29.7% of the patients with secondary ECMO implantation,
additional cardiac procedures (coronary artery bypass grafting
[CABG] or CABG revision in 60%) were performed.
ECMO support lasted 3.3  2.9 days (range, 0–25 days).
During that period, surgical ECMO revision for unsatisfac-
tory ECMO flow was required in 12.5% of the patients,
and such an event was associated with significantly higher
in-hospital mortality (OR, 2.24; P ¼ .042). Exchange of
the oxygenator was required in 6.1% at a mean of 3.0
days after first ECMO implantation. Arterial cannulation
site did not significantly influence hospital outcome, but
percutaneous venous femoral cannulation was associated
with adverse outcome. For more details, see Table E1.304 The Journal of Thoracic and Cardiovascular SurgSuccessful ECMO weaning was possible in 63.5% of the
cases. Overall, 56.4% patients survived ECMO explantation
for longer than 24 hours. Overall, in-hospital mortality was
75.2%, with the main reason for death being cardiac in
79.9%. Patients died a mean of 11.1 days after ECMO im-
plantation. As shown in Tables 1 through 3, several preoper-
ative risk factors significantly influenced hospital outcome;
of these, however, only age older than 70 years (OR, 1.90;
P ¼ .022), diabetes (OR, 2.61; P ¼ .001), and isolated cor-
onary artery disease (OR, 0.56; P¼ .025) were significant in
multivariate analysis. Despite failure to reach statistical sig-
nificance, there was a strong trend toward worse outcome
among patients with additional tricuspid regurgitation
greater than 2þ, acute type A dissection, and combined aortic
and mitral valve disease, whereas preoperative emergency
status, preoperative AMI, and active mechanical resuscita-
tion before ECMO implantation were not significant predic-
tors for in-hospital death (Table 2).
In-hospital mortality also depended significantly on the
primary cardiac procedure (Table 3). Hospital survival was
significantly improved for patients undergoing isolated
CABG (34.7%) with surrogates of coronary artery disease
and worse for patients undergoing aortic arch repair or total
pericardiectomy, indicating that the complexity of the pri-
mary cardiac procedure significantly influenced outcome af-
ter ECMO implantation.
ECMO outcomewas also significantly associated with the
severity of pre-ECMO PCS and with circulatory and meta-
bolic recovery during ECMO support, as indicated by lactate
level changes. Lactate level greater than 10 mmol/L imme-
diately after ECMO implantation was a significant predictor
of mortality (mortality, 83.0%; OR, 2.65; P<.001). Persis-
tent lactate values greater than 10 mmol/L after 24 and 48
hours of ECMO support were associated with the highest
mortalities of 93.6% (OR, 8.2; P< .001) and 97.6% (OR,
22.5; P<.001), respectively. Serologic signs of liver necro-
sis (OR, 3.25; P< .001) and acute renal failure (OR, 4.27;
P < .001) during ECMO were strongly associated with
in-hospital mortality.
A total of 54.3% of the patients had AMI according to the
definition mentioned previously. Creatine kinase MB levels
greater than 120 units/L after 24 and 48 hours of ECMO
assistance were also associated with increased mortalities
of 78.6% (OR, 1.73; P< .001) and 81.0% (OR, 2.36;
P< .001), respectively.
There was a considerable complication rate among pa-
tients undergoing ECMO (Table 4). High blood loss during
the first 24 hours of ECMO (survivors 2532 mL vs nonsur-
vivors 3261 mL, P ¼ .019) and the event of acute renal fail-
ure (OR, 4.37; P< .001) significantly impaired hospital
survival, whereas the total amount of blood product transfu-
sion and rethoracotomy did not. Overall hospital stay was
16.2 days, with a mean of 27.2 days among the hospital
survivors.ery c February 2010
TABLE 1. Patient demographic data and preoperative clinical status with respect to hospital outcomes
In-hospital mortality
Characteristic
All
(n ¼ 517)
Hospital survivors
(n ¼ 128)
Nonsurvivors
(n ¼ 389)
Hospital
survival (%) OR 95% CI
P
value
Extracardiac characteristics
Age (y, mean  SD) 63.5  11.2 60.4  12.3 64.0  10.7 .002
>70 y (%) 29.8% 22.6% 32.2% 18.7% 1.62 1.01–2.69 .049
Sex (% female) 28.5% 27.0% 29.0% 23.5% 1.11 0.69–1.78 .671
BMI>30 (%) 21.8% 14.8% 24.1% 16.8% 1.83 1.04–3.25 .037
Diabetes (%) 32.5% 19.1% 36.9% 14.7% 2.47 1.48–4.13 .001
Hyperlipidemia (%) 47.4% 52.2% 45.8% 27.4% 0.78 0.51–1.18 .238
Arterial hypertension (%) 70.3% 69.6% 70.6% 24.6% 1.05 0.66–1.66 .832
COPD (%) 13.0% 9.6% 14.1% 18.3% 1.55 0.78–3.09 .214
Smoker (%) 27.5% 37.4% 24.2% 33.9% 0.54 0.34–0.84 .006
Renal insufficiency (%) 15.6% 9.2% 17.6% 14.3% 2.11 1.04–4.29 .038
Preop neurologic impairment (%) 7.8% 4.3% 8.9% 13.9% 2.15 0.82–5.67 .121
Peripheral vascular disease (%) 23.5% 17.4% 25.6% 18.3% 1.63 0.95–2.80 .075
Cardiac characteristics
Preop AF (%) 19.9% 14.8% 21.6% 18.5% 1.58 0.89–2.81 .117
s/p PM/ICD implantation (%) 10.4% 9.6% 10.6% 22.9% 1.12 0.55–2.29 .745
Pulmonary hypertension (%) 14.1% 10.5% 15.3% 18.5% 1.53 0.79–2.98 .209
Previous cardiac surgery (%) 23.8% 18.3% 25.6% 19.1% 1.54 0.91–2.62 .112
s/p AMI (%) 38.0% 46.1% 35.3% 30.3% 0.64 0.42–0.98 .039
s/p PCI (%) 20.3% 29.6% 17.3% 36.2% 0.50 0.31–0.81 .005
Ejection fraction (%, mean  SD) 45.9%  17.6% 46.1%  17.2% 45.8%  17.8% .858
<30% (%) 19.0% 15.9% 20.0% 20.9% 1.32 0.75–2.33 .340
CCS angina class IV (%) 15.6% 18.3% 14.8% 29.6% 0.78 0.44–1.36 .375
NYHA functional class IV (%)
AMI
23.6% 21.1% 24.4% 22.2% 1.21 0.73–2.02 .464
<12 h (%) 16.2% 15.7% 16.4% 22.2% 1.18 0.60–2.32 .636
STEMI 8.5% 7.0% 9.0% 20.5% 1.33 0.59–2.98 .490
NSTEMI 7.7% 8.7% 7.4% 32.3% 0.68 0.31–1.50 .344
Preop cardiogenic shock (%) 17.7% 16.5% 18.1% 23.2% 1.12 0.64–1.96 .700
Preop IABP insertion (%) 9.5% 13.0% 8.3% 34.1% 0.61 0.31–1.18 .139
Preop ventilation (%) 14.9% 14.8% 14.9% 24.6% 1.01 0.56–1.83 .967
Preop inotropic support (%) 19.7% 16.5% 20.7% 20.9% 1.32 0.76–2.30 .311
Emergency indication (%) 39.7% 38.3% 40.2% 25.8% 1.09 0.71–1.67 .708
Urgent indication (%) 23.6% 17.7% 25.6% 18.5% 1.60 0.93–2.74 .089
Resuscitation in operating room (%) 6.0% 3.5% 6.9% 14.3% 2.06 0.70–6.10 .191
Logistic EuroSCORE (%, mean  SD) 21.6%  20.7% 14.7%  14.4% 23.9%  21.9% <.001
EuroSCORE>20% (%) 40.0% 29.6% 43.4% 18.4% 1.83 1.16–2.87 .009
AMI, Acute myocardial infarction; BMI, body mass index; CI, confidence interval; CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary disease; IABP,
intra-aortic balloon pump; ICD, implantable cardioverter defibrillator; PM, pacemaker; Postop, postoperative; Preop, preoperative; NSTEMI, Non–ST-segment elevation myocar-
dial infarction; NYHA, New York Heart Association; OR, operation room; s/p, status post; STEMI, ST-segment elevation myocardial infarction.
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DFive patients with ECMO were bridged to transplantion.
Of these, 2 survived. Twelve of 15 patients who received
bridge-to-bridge left VAD implantation after a mean of 3.2
 1.2 days of ECMO died during the hospital stay.
Overall cumulative survivals were 31.3%  2.2% after
30 days, 17.6%  1.8% after 6 months, 16.5%  1.7%
after 1 year, and 13.7%  1.7% after 5 years (Figure 1).
Patients with isolated CABG procedures had the best early
(41.0%  3.7% after 30 days) and long-term (22.2% 
3.2% after 1 year and 19.6%  3.1% after 5 years)
survivals. Five-year survival for all hospital survivors was
55.8%  5.0%.The Journal of Thoracic and CaDISCUSSION
ECMO Indication
Patients with persistent PCS despite optimal medical
treatment and IABP face almost certain death, and all treat-
ment alternatives have to be assessed in the light of an other-
wise dismal prognosis. ECMO is a reasonable treatment
option for temporary mechanical circulatory support in these
patients and was preferred in our institution relative to other
assist devices because of its versatility. ECMO allows rapid
restoration of circulation during primary cardiac surgery or
active resuscitation, fits with almost all patients and clinical
scenarios, is cost saving, offers varying cannulation options,rdiovascular Surgery c Volume 139, Number 2 305
TABLE 2. Underlying cardiac diseases
In-hospital mortality
Characteristic
All
(n ¼ 517)
Hospital survivors
(n ¼ 128)
Nonsurvivors
(n ¼ 389)
Hospital
survival (%) OR 95% CI
P
value
CAD
All 69.1% 77.4% 66.4% 27.8% 0.58 0.35–0.94 .028
1-vessel 12.8% 7.9% 14.7% 17.1% 1.67 0.72–3.88 .232
2-vessel 20.3% 24.7% 18.6% 33.8% 0.60 0.34–1.05 .072
3-vessel 66.9% 67.4% 66.7% 28.0% 0.73 0.48–1.11 .140
Left main disease 27.5% 28.1% 27.3% 28.4% 0.80 0.47–1.34 .390
Isolated CAD 44.1% 56.5% 39.9% 31.9 0.51 0.33–0.79 .002
AV disease 20.3% 15.7% 21.8% 19.1 1.51 0.86–2.65 .155
Isolated AV disease 8.2% 7.0% 8.6% 21.1 1.26 0.56–2.84 .574
CAD and AV disease 7.9% 7.0% 7.8% 22.9 1.12 0.50–2.55 .778
MV disease 19.7% 15.7% 21.0% 19.8 1.43 0.81–2.52 .215
Isolated MV disease 4.1% 3.5% 4.3% 21.1 1.25 0.41–3.85 .617
CAD and MV disease 9.9% 10.4% 9.8% 26.1 0.93 0.46–1.86 .836
Isolated AV and MV disease 1.7% 0.0% 2.3% 0 .210
CAD, AV, and MV disease 2.6% 1.7% 2.9% 16.7 1.67 0.36–7.74 .551
TV regurgitation>2þ 3.7% 0.9% 4.6% 5.6 5.95 0.72–41.9 .100
Bacterial endocarditis 4.5% 3.5% 4.9% 19.0 1.43 0.47–4.33 .530
Type A dissection 3.9% 0.9% 4.9% 5.6 5.86 0.77–49.5 .088
Pulmonary embolism 1.5% 1.7% 1.4% 28.6 0.82 0.16–4.30 .818
Thoracic aneurysm 7.3% 7.8% 7.2% 26.5 0.91 0.41–2.01 .819
Other isolated disease 5.4% 4.3% 5.7% 19.3 1.34 0.49–3.66 .566
All figures are percentages of patients. Cardiac diseases are not mutually exclusive and therefore total more than 100%. AV, Aortic valve; CAD, coronary artery disease; CI, con-
fidence interval; MV, mitral valve; OR, odds ratio; TV, tricuspid valve.
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Dand covers biventricular and lung function. The last is of
substantial importance in active resuscitation secondary to
surgery and emergency operations, where the underlying
reason for PCS sometimes cannot be completely fixed. In
these cases, ECMO allows bridging of patients for further
evaluation and decision making and judgment of neurologic
status. From the economic perspective, ECMO also provides
circulatory support for older patients with relevant comor-
bidities, giving them at least the chance for cardiac or respi-
ratory recovery even if VAD implantation or transplantion is
not a further option. In this group, termination of ECMO is
warranted if no rapid clinical improvement is seen.
Amajor disadvantage of ECMO is the need for anticoagu-
lation and the requirement of high amounts of transfused
blood products, increasing the systemic inflammatory re-
sponse that is induced by the initial surgery, the ECMO com-
ponents, and PCS itself. Thus indication for temporary
ECMO support for PCS always depends on patient-specific
characteristics and center experience, balancing risks and
benefits. In our 12-year experience with 517 patients under-
going ECMO for PCS, we evaluated several risk factors for
adverse hospital outcome to support decision making in the
future.
In-Hospital Mortality
For all our patients with ECMO, native cardiopulmonary
recovery was the primary intention, because most patients306 The Journal of Thoracic and Cardiovascular Surgwere neither transplantion candidates nor candidates for fur-
ther assist device implantation. Overall, successful weaning
from the system was possible for 63.3% of the patients, but
more than 50% of the weaned patients died during the hos-
pital stay. Hospital survival thus was limited to 25%, which
is comparable to results of smaller series of patients with
PCS undergoing ECMO for which early survivals between
16% and 41% have been reported.3-11 These data demon-
strate that high mortality has continued to plague temporary
circulatory ECMO support. They also suggest that despite
progress in intensive care management and ECMO hardware
components, in-hospital mortality has not significantly
changed during the last decade. This finding is indeed sup-
ported by our experience that ECMO survival was relatively
constant during the 12-year period, except during the last
3 years in which there was an improved survival greater
than 30% (data not shown). It can be speculated, however,
that there has been an improvement in ECMO results that
does not directly translate to mortality reduction but rather
reaches the same results for older and sicker patients. This
hypothesis is supported by our finding that about 2 thirds
of our patients could be successfully weaned from ECMO
despite increases in risk scores, patient age, and complexity
of cardiac procedures.
Of note, we did not find an improved outcome for 15 pa-
tients after early conversion to an implantable left ventricular
assist device (L-VAD). This finding contrasts with otherery c February 2010
TABLE 3. Cardiac procedures
In-hospital mortality
Characteristic
All
(n ¼ 517)
Hospital survivors
(n ¼ 128)
Nonsurvivors
(n ¼ 389)
Hospital
survival (%) OR 95% CI
P
value
All CABG (%) 61.8% 70.4% 58.9% 28.3% 0.60 0.38–0.95 .028
Left internal thoracic artery (%) 69.4% 82.0% 64.5% 0.40 0.22–0.73 .003
Bilateral internal thoracic artery (%) 5.0% 10.1% 3.0% 0.28 0.10–0.77 .014
Complete revascularization (%) 82.2% 84.0% 78.0% 0.68 0.35–1.30 .237
Distal anastomoses (no., mean  SD) 2.16  1.27 2.30  1.24 2.10  1.27 .202
Isolated CABG (%) 37.4% 52.2% 32.5% 34.7% 0.44 0.29–0.68 <.001
Distal anastomoses (no., mean  SD) 2.49  0.99 2.56  1.00 2.46  0.98 .482
AV surgery (%) 32.0% 26.1% 33.9% 20.3% 1.45 0.91–2.33 .120
Isolated AV surgery (%) 7.6% 7.8% 7.5% 25.7% 0.95 0.43–2.09 .901
CABG and AV surgery (%) 5.4% 2.6% 6.3% 12.0% 2.52 0.74–8.58 .139
MV surgery (%) 24.8% 15.7% 27.9% 15.7% 2.08 1.20–3.63 .010
Isolated MV surgery (%) 3.9% 1.7% 4.6% 11.1% 2.72 0.62–12.0 .186
CABG and MV surgery (%) 5.8% 5.2% 6.0% 22.2% 1.17 0.46–2.97 .746
Isolated AV and MV surgery (%) 2.8% 0.9% 3.4% 7.7% 4.07 0.52–31.7 .180
CABG, AV, and MV surgery (%) 2.8% 1.7% 3.2% 15.4% 1.84 0.40–8.45 .430
TV repair (%) 4.3% 2.6% 4.9% 15.0% 1.92 0.55–6.67 .306
Ascending aorta surgery (%) 13.2% 11.3% 13.9% 21.3% 1.26 0.65–2.41 .495
Aortic arch repair (%) 3.7% 0.9% 4.6% 5.9% 5.49 0.72–41.9 .100
Surgical ventricular restoration (%) 1.7% 1.7% 1.7% 25.0% 0.99 0.20–4.98 .991
Ischemic VSD closure (%) 1.1% 0.9% 1.1% 20.0% 1.33 0.15–12.0 .802
Pulmonary embolectomy (%) 1.5% 1.7% 1.4% 28.6% 0.82 0.16–4.30 .818
Pericardiectomy (%) 1.1% 0.0% 1.4% 0.0% .090
Thoracic transplantion (%) 6.5% 6.1% 6.6% 23.3% 1.09 0.46–2.62 .844
Operative time (min, mean  SD) 275  140 265  126 279  144 .342
CPB time (min, mean  SD) 179  106 160  94 185  110 .031
Crossclamp time (min, mean  SD) 84.6  51.5 75.6  50.1 87.4  52.0 .068
First operating room lactate level
>4 mmol/L (%)
13.8% 7.8% 15.8% 2.21 1.06–4.63 .035
Operation end lactate level>4
mmol/L (%)
63.3% 53.0% 66.7% 1.77 1.15–2.72 .009
IABP insertion
Total (%) 74.1% 77.4% 73.0% 0.79 0.48–1.30 .351
Intraoperative (%) 32.0% 33.9% 31.3% 0.89 0.57–1.39 .606
Postoperative (%) 37.6% 34.8% 38.5% 1.17 0.76–1.82 .475
Cardiac procedures are not mutually exclusive. AV, Aortic valve; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, confidence interval; CPB, cardiopul-
monary bypass; IABP, intraaortic balloon pump; MV, mitral valve; OR, odds ratio; TV, tricuspid valve, VSD, ventricular septal defect.
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after an early switch to long-term L-VAD support.5,7,13
This remarkable difference may easily be explained by
selection bias; however, it can also be speculated that time
of conversion, type of implanted L-VAD, and underlying
cardiac disease play critical roles in success of this bridge-
to-bridge concept.
Patient and Cardiac Surgery Risks for In-Hospital
Death
Patient-specific and procedural predictors for in-hospital
death among patients undergoing ECMO are not well
defined in the literature. In an analysis of 202 adult patients
undergoing ECMO, Smedira and colleagues1 recently foundThe Journal of Thoracic and Cathat previous cardiac surgery, older age, thoracic aortic op-
eration, and the nonuse of IABP were significant predictors
for death. This was particularly confirmed by our findings
that age older than 70 years, obesity, and diabetes were
independent risk factors for in-hospital mortality, whereas
there was only a strong trend for worse survival in thoracic
aortic surgery and nonuse of IABP. Advanced age alone,
however, cannot serve as an absolute contraindication for
ECMO implantation.6,14 We additionally found that preop-
erative critical status itself (eg, mechanical ventilation, ino-
tropic support, active intraoperative resuscitation) was not
associated with increased in-hospital mortality, whereas
severity of PCS as measured by preoperative lactate values
was.rdiovascular Surgery c Volume 139, Number 2 307
TABLE 4. Postoperative complications
Rethoracotomy
Total (no.) 425 (82.2%)
For bleeding (no.) 300 (58.0%)
For sternal wound revision (no.) 20 (3.9%)
IABP support (d, mean  SD) 5.93  5.31
Ventilation
Total ventilation time (h, mean) 339
Reintubation (no.) 119 (23.2%)
Tracheostomy (no.) 95 (18.4%)
Pneumonia (no.) 111 (21.5%)
Adult respiratory distress syndrome (no.) 48 (9.3%)
Postoperative drainage loss (mL)
First 24 h 3080
First 48 h 4245
Blood product transfusion in first 48 h
Total (units, mean  SD) 29.4  25.6
Red blood cells (units, mean  SD) 13.6  12.1
Fresh-frozen plasma (units, mean) 14.0  13.0
Platelets (units, mean  SD) 1.72
Renal replacement therapy
Use (no.) 336 (65.0%)
Duration (d) 9.7
ECMO leg complications
Leg ischemia (no.) 28/141 (19.9%)
With distal leg perfusion cannula (no.) 3/33 (9.1%)
Without distal leg perfusion cannula (no.) 25/108 (23.1%)
Leg fasciotomy (no.) 13/141 (9.2%)
With distal leg perfusion cannula (no.) 1/33 (3.0%)
Without distal leg perfusion cannula (no.) 12/108 (11.1%)
Gastrointestinal complication (no.) 97 (18.8%)
Laparotomy (no.) 28 (5.4%)
Cerebrovascular events
Total (no.) 90 (17.4%)
Cerebral bleeding (no.) 19 (3.7%)
Cerebral stroke (no.) 28 (5.4%)
New atrial fibrillation (no.) 103 (19.9%)
ECMO, Extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump.
FIGURE 1. Cumulative survival curve indicating freedom from death of
any cause after extracorporeal membrane oxygenation implantation for
postcardiotomy cardiogenic shock. Mean follow-ups were 0.82 years for
all patients and 3.2 years for hospital survivors.
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and the corresponding cardiac procedure had significant ef-
fects on hospital survival after ECMO for PCS. One impor-
tant finding was that isolated CABG had the best prognosis
of all operative procedures, with an in-hospital survival of
44%. Internal thoracic artery use provided supplementary
protection. This is consistent with the findings of Magovern
and Simpson,8 who demonstrated increased survival for
patients with ECMO after isolated CABG. In contrast to
CABG, we found that patients with mitral valve surgery
had a significantly worse prognosis after ECMO implanta-
tion. Moreover, there was a clear trend for aortic arch
surgery (5.9% survival) and pericardiectomy (no survival)
to be associated with bad prognosis, probably because of
intractable bleeding complications from the large wound
surface. It would be of utmost interest to know a critical
combination of underlying diseases or surgical procedure
that makes risk of ECMO implantation prohibitively high.308 The Journal of Thoracic and Cardiovascular SurgWe cannot recommend absolute refusal ECMO in any par-
ticular case; however, our results demonstrate that prognosis
for patients with ECMO after type A dissection, constrictive
pericarditis, or double-valve disease is extremely limited.ECMO Management
On the basis of our results, implementation of ECMO
should be considered early in the face of cardiac pump fail-
ure. If a general decision for ECMO support is made, it is
reasonable not to wait until secondary organ damage, resus-
citation, or profound metabolic acidosis has occurred.
Therewas noadvantage of a central arterial cannulation site
relative to a peripheral site or to an axillary artery approach
relative to a femoral artery approach. In contrast, percutane-
ous femoral vein drainage was associated with a worse prog-
nosis and may be a surrogate for suboptimal venous drainage
and compromised ECMO flow. Like others, we found that
any ECMO revision was associated with poor prognosis.14
We also found no difference between simultaneous and
secondary ECMO implantations. Among cases of secondary
indications, however, nonsurvivors had a significant longer
interval between primary cardiac surgery and ECMO im-
plantation. This group represents more patients with sudden
cardiac death receiving ECMO as a last resort, with compa-
rably worse prognosis.ECMO Predictors for In-Hospital Death
Like others, we found several significant predictors for in-
hospital mortality during ECMO support, including acute
liver and renal failure.4 Findings of persistent anaerobic
metabolism after 24 and 48 hours of ECMO support, asery c February 2010
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gest predictors for mortality. On the basis of these findings,
we recently started to use bicarbonate dialysis in the very
early post-ECMO period to prevent severe metabolic acido-
sis when ECMO flow was appropriate.
AMI was a common finding among patients undergoing
ECMO and was associated with poor outcome. This is in ac-
cordance with Zhang and colleagues,10 who demonstrated
a strong relationship between creatine kinase MB release
during ECMO and in-hospital mortality. In contrast to our
measurement, Zhang and colleagues10 used the ratio of
creatine MB to total creatine kinase.
Complication Rate
ECMO was associated with significant morbidity. Leg is-
chemia occurred in our series in a total of 5.4% patients, and
in 19.9% of legs with femoral artery ECMO cannulation.
This is comparable with limb ischemia rates reported by
others.1,4 We found that the use of a distal leg perfusion can-
nula reduced leg ischemia and fasciotomy to less than 40%,
and we therefore recommend this whenever the femoral
artery is used for ECMO implantation.
Despite the administration of antifibrinolytic agents, se-
lective coagulation factors, and blood product transfusions,
postoperative bleeding was among the major problems in
postoperative ECMO care. Reasons for excessive bleeding
in these patients included the surgical trauma, thrombocyto-
penia, activation of leucocytes, and anticoagulation treat-
ment. Excessive bleeding led to rethoracotomy in more
than half of the patients. Mean perioperative red blood cell
transfusion rate was 13 units/patient during the first 48 hours
of ECMO support. Golding and coworkers15 reported
a mean transfusion rate of 53.2 packed red blood cell
units/patient and a rethoracotomy rate of 87.3% among 91
patients undergoing ECMO. In other studies of ECMO for
PCS, rethoracotomy for bleeding was required in 40.0%
and 53.2% of patients, respectively.4,16
Cerebrovascular events occurred in 17.4% of all our pa-
tients. Smedira and colleagues1 reported that 33% of 202 pa-
tients had significant neurologic injury. In previous studies,
others found neurologic complications among 10.0% to
16.0% of adult patients undergoing ECMO4,15,16; however,
we demonstrated by autopsy studies that 51.9% of all cere-
bral pathologic conditions in patients undergoing ECMO
were clinically undetected.12 Even if it is difficult to assign
the cerebral event to the operative procedure, the critical
pre-ECMO circulatory state, or the ECMO run itself, the
overall risk of neurologic events must be kept in mind and
should lead to morphologic diagnostic evaluation before
further major therapy is considered.
Follow-up
Despite the high in-hospital mortality, we should keep in
mind that the overall long-term survival of patients afterThe Journal of Thoracic and CaECMO for PCS is comparable to data known from lung
cancer. Recently, a Finnish group demonstrated an overall
5-year survival with lung cancer of 12% in 602 patients of
comparable age.17 The long-term-survival of hospital survi-
vors after ECMO for PCS is good, however, demonstrating
that the early mortality is the Achilles heel in ECMO ther-
apy. We found a 56% 5-year survival for hospital survivors.
These data are comparable to the Cleveland Clinic experi-
ence with an unselected ECMO population, in which pa-
tients surviving 30 days had a 63% chance of being alive
after 5 years.1 Smith and colleagues18 from Melbourne
also found an excellent long-term survival and satisfactory
quality of life in an older population of hospital survivors af-
ter ECMO. The finding regarding quality of life was recently
confirmed by detailed measurements of mental health and
vitality in 28 long-term survivors after ECMO.18
Limitations
Even though the data collection was performed prospec-
tively, this study is subject to all limitations inherent in a non-
randomized study.
CONCLUSIONS
This study was performed to analyze the outcome of tem-
porary ECMO support for the indication of PCS. In this se-
ries, overall hospital survival was 24.8%. Patients with
isolated CABGhad the best outcome, whereas high extracar-
diac morbidity and profound and ECMO-resistant PCS were
significant risk factors for in-hospital mortality. Because
prognosis of patients undergoing ECMO for PCS depends
significantly on the depth of PCS at implantation, it is wise
not to wait too long when ECMO is a reasonable option.
Long-term outcome of hospital survivors was relatively
good. Because of the high morbidity, however, ECMO has
to be considered on the basis of individual risk profile and
underlying cardiac disease. Because of the high device-re-
lated morbidity, further efforts have to be made to develop
less traumatic devices, allowing fast and easy application
for temporary circulatory support.19
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Dr R. Duane Davis (Durham, NC). Dr Rastan and colleagues
have reported on a large cohort of patients with PCS supported
by ECMO. Not surprisingly, for this difficult group of patients,
this experience featured substantial mortality and morbidity, partic-
ularly bleeding and thromboembolic complications. The hospital
survival of approximately 25% is similar to numerous previous re-
ports as well as to registry data, which are approximately in the 30%
to 35% range. So their results are well within the range of what we
would expect. My questions are going to be related first to technical
issues, second to patient selection issues, and third to overall stra-
tegic issues.
First, Dr Rastan, you have suggested that ongoing shock, as
manifested by lactate levels that are increasing or high at the begin-
ning, is associated with worse outcomes in terms of mortality. Is
this an opportunity? That is, do you have data to suggest that if
you are able to increase the performance while on ECMO by in-
creasing ECMO flow rates or improving the blood pressure that
you can actually improve outcomes? From that standpoint, is there
a strategy when you have ongoing higher lactate levels or shock of310 The Journal of Thoracic and Cardiovascular Surgaltering cannula positions or other things to try to improve ECMO
performance?
Dr Rastan. This is an important point. What we sometimes
found in our experience is that we had some problems with the ve-
nous backflow to the ECMO system if we used femoral cannulation
sites. As a consequence, this was one of the main reasons for
ECMO revision. In these patients, we found an ongoing high lactate
level during the first 24 hours because we had a flow of only 80% to
90% of the cardiac output. This was in a few patients an indication
for reopening the chest to put in a right atrial cannulation. So in ad-
dition to bleeding, compromised ECMOflowwas indeed one of the
most important reasons for ongoing high lactate levels, and we
could show that this was associated with extremely high mortality.
Dr Davis. Let me follow up on that. Have you changed your
strategy during the years—earlier implantation, more open-chest
procedures, more central cannulation—or is it still a kind of mish-
mash of approaches to these patients?
Dr Rastan. Yes, we changed our policy twice. With the intro-
duction of long venous femoral cannulas, our policy changed to
close the chest and to use peripheral cannulation—axillary or fem-
oral arterial cannulation—to reduce bleeding complications. In our
experience, however, some of these patients had suboptimal
ECMO flow, so we changed the strategy again and used thoracic
cannulation more liberally to allow an optimal ECMO flow.
The latter strategy is also supported by the experience that even
with peripheral cannulation and a closed chest, most of the pa-
tients required rethoracotomy because of hematoma, which com-
promised the cardiac function, whereas there was bleeding and
a low infection rate in open-chest patients. So we think that clos-
ing the chest is not the primary goal for every patient undergoing
ECMO.
Dr Davis. My second question really regards patient selection.
When is the use of ECMO really going to be futile? You have
shown a statistical analysis, which basically assumes a linear rela-
tionship with a number of variables, but we all know that for age,
for instance, the relationship may be linear for a long time, but as
you approach the 70s and 80s it actually becomes more of an expo-
nential relationship. That is, would you put an 80-year-old patient
on ECMO after dissection repair in your institution? Whom do you
exclude?
Dr Rastan. This is a difficult point. Our policy was to use
ECMO liberally in PCS situations. We put not all but almost all pa-
tients in PCS on ECMO. This included older patients, allowing
them cardiac recovery for at least 2 to 3 days. If this failed and
the cardiac failure persisted, we withdrew ECMO therapy in
consensus with the families.
I think that especially in unexpected PCS, that is, for patients
with primary good cardiac function or after uneventful early post-
operative course, there is a good chance for cardiopulmonary re-
covery. This is why we do not reject implantation of ECMO
even for an older patient. What we have to rethink, however, on
the basis of these data is whether after complex valve or aortic pro-
cedures with a high bleeding rate we should decide to turn down
ECMO or withdraw it earlier.
Dr Davis. My final question regards the appropriate strategy in
2009 or 2010 for the support of a patient after PCS? In this series,
you didn’t have a substantial improvement during the 12-year pe-
riod. If you look at the literature, there also doesn’t appear to be
much of an improvement during that period. Your 6-month survivalery c February 2010
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but is that really where we should be headed? Can’t we do better?
Now, this question is kind of multiphase. It has to do with some
institutional bias in that we try to direct our therapy to what is fail-
ing. That is, if it is a left ventricular failure, we’ll put an L-VAD in;
if it is a left ventricular failure, if it is a right ventricular failure, we’ll
put a right VAD in; if it is just pulmonary, parenchymal, or gas ex-
change, then we use venovenous ECMO. We use venoarterial
ECMO more along the lines of 2 or 3 failures, right ventricle, left
ventricle, lung. Do you have an approximation of how many of
the patients had right ventricular failure, left ventricular failure, pa-
renchymal failure, or a combination? And are you moving away
from using venoarterial ECMO to some of the other treatment
modalities? You may actually have more tools in your chest than
we have in the United States.
Dr Rastan. First, our data revealed an improved survival gain
during the last 3 years in our institution, which I didn’t show
here. We all know that the survival and the success of ECMO de-
pends heavily on patient selection. In other words, if you include
unfavorable patients in your cohort and implant ECMO, you will
have a bad outcome. So the results depend strongly on the indica-
tion and the selection before the ECMO implantation. As I demon-
strated, we used ECMO liberally and included some very poor
candidates. Surprisingly, a significant number even of these
patients survived.
The reasons we preferentially used ECMO rather than other life-
saving systems, especially for the postoperative indications, were
that we can implant it quickly, that ECMO fits all patients, and
that ECMO covers both right and left ventricular as well as pulmo-
nary failure, which sometimes is difficult to distinguish in an emer-
gency situation. I agree with you that if you can fix left ventricular
failure, maybe a centrifugal pump just for support of the left ventri-
cle might be the better option to reduce systemic inflammatory re-
sponse syndrome or the high bleeding rate. This is difficult to fix inThe Journal of Thoracic and Caan individual situation or under resuscitation, however, so our
policy is to use ECMO more often than isolated centrifugal pumps.
Not surprisingly, we found left ventricular failure in most of our
patients. For patients with right ventricular failure, we had the ex-
perience that cardiac recovery was more prolonged or failure more
frequent. Thus patients with right heart failure had worse outcome
than patients with left ventricular failure.
In a total of 15 younger patients, we implanted an L-VAD as
a bridge-to-bridge therapy. To be honest, though, these data were
unsatisfactory. We lost 12 of these 15 patients in the postoperative
course. Maybe the concept is to fix the problem as fast as possible
under ECMO and then to switch as early as possible to a more du-
rable system if the patient is a transplantion candidate. Most of our
patients were not transplantion candidates, or were poor candidates,
as I could demonstrate to you. A lot of our patients had emergency
or urgent indications for surgery.
Dr Davis. I guess my comment with regard to ECMO and trying
to get left ventricular recovery is it is really not an unloading strat-
egy. It is, rather, a loading strategy, and then you throw in all the
thromboembolic complications that run with having essentially
a membrane oxygenator and circuit, it seems to be a bit problem-
atic. But my congratulations on an excellent presentation.
Dr Thorsten Hanke (Lu¨beck, Germany). I have a single ques-
tion. There was a difference between patients in whom you im-
planted the ECMO early in the operating room and those in
whom you did it after 2 or 3 days. Has there been a difference in
the outcome between those patient groups?
Dr Rastan. No. Just a short answer. This was interesting, be-
cause there might be a difference in patient characteristics between
patients who received ECMO because they were not able to be
weaned from cardiopulmonary bypass and other patients who
had primarily good or acceptable condition with an IABP and
low catecholamines and then had PCS. But this event per se was
not an indicator for hospital mortality in univariate analysis.rdiovascular Surgery c Volume 139, Number 2 311
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FIGUREE1. Univariate andmultivariate analyses of in-hospital mortality,
including 54 preoperative and 42 procedural variables. Only significant
variables are demonstrated. Odds ratios are depicted with 95% confidence
intervals, indicating significance when not crossing midline bar. Variables
labeled with asteriskwere also significant in multivariate logistic regression
analysis.CAD,Coronary artery disease; s/p, status post; AMI, acute myocar-
dial infarction; PCI, percutaneous coronary intervention.
TABLE E1. Extracorporeal membrane oxygenation implantation details and outcomes
In-hospital mortality
Characteristic All (n ¼ 517) Hospital survivors (n ¼ 128) Nonsurvivors (n ¼ 389) OR 95% CI P value
Simultaneous ECMO implantation (%) 41.9% 45.2% 40.8% 0.84 0.55–1.28 .406
Secondary ECMO implantation (%) 58.1% 54.8% 59.2% 1.20 0.78–1.83 .406
Time after primary surgery (h) 62.6 33.3 71.7 .031
Optimal time of ECMO implantation
(h, mean  SD)
111  79 104  70 113  82 .420
Additional cardiac surgery (%) 29.7% 30.2% 29.6 0.97 0.64–1.48 .892
Arterial cannulation
Central (%) 60.8% 62.2% 60.3% 0.91 0.59–1.40 .666
Peripheral (%) 39.2% 37.8% 39.7% 1.05 0.68–1.62 .831
Axillary (%) 11.9% 9.6% 12.6% 1.37 0.68–2.75 .378
Femoral (%) 27.3% 28.2% 27.1% 1.00 0.62–1.63 .998
Leg perfusion (% of femoral) 23.4% 29.1% 21.4% 0.65 0.23–1.78 .399
Venous cannulation*
Central (%) 61.8% 62.6% 61.5% 0.95 0.62–1.47 .831
Femoral (%) 48.2% 40.0% 50.9% 1.55 1.01–2.38 .044
Percutaneous (%) 20.3% 13.9% 22.4% 1.79 0.99–3.21 .052
Open (%) 27.9% 26.1% 28.4% 1.13 0.70–1.81 .624
Open chest (%) 50.8% 53.9% 49.7 0.85 0.59–1.29 .435
Surgical ECMO revision (%) 12.5% 7.0% 14.4 2.24 1.03–4.89 .042
Oxygenator exchange (%) 6.9% 3.5% 8.0 2.42 0.83–7.08 .104
ECMO support
Duration (d, mean  SD) 3.28  2.85 2.99  1.93 3.38  3.09 .210
>5 d (%) 20.1% 14.8% 21.8 1.61 0.91–2.86 .104
OR, Odds ratio; CI, confidence interval; ECMO, extracorporeal membrane oxygenation. *Venous central and femoral cannulations are not exclusive because of revisions for
insufficient venous drainage.
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